Riskpilot← Back to searchSign inGet full accessMedspec AB
ABActiveOrg 5591515845Rådmansgatan 15General medical practice activities · NACE 8621Est. 20181 employees
Revenue 2024
SEK 2,1M
0% vs 2023
EBITDA margin
27.6%
-6% vs 2023
Equity ratio
67.2%
Financial strength
Net profit 2024
SEK 465K
-7% vs 2023
| Revenue | SEK 2,1M | +0% |
| EBITDA | SEK 586K | -6% |
| Net profit | SEK 465K | -7% |
| Total assets | SEK 767K | -18% |
| Equity | SEK 516K | -6% |
| Employees | 1 | — |
Legal name
Medspec AB
Org number
5591515845
Legal form
Aktiebolag
NACE code
8621 · General medical practice activities
Founded
6 mars 2018
Share capital
SEK 50 000
Employees
1 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Föremålet för bolagets verksamhet är Medcinska konsult- och läkartjänster och därmed förenlig verksamhet.
Address
Rådmansgatan 15
Email
olczykowski@me.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 1 496 | 1 493 | 1 764 | 2 132 | 2 124 |
| Staff expenses | — | — | −1 040 | −1 208 | −1 249 |
| EBITDA | 215 | 289 | 525 | 625 | 586 |
| Depreciation & amort. | −0 | −0 | — | — | — |
| EBIT | 215 | 289 | 525 | 625 | 586 |
| Net financials | — | — | −0 | 3 | 1 |
| Profit before tax | 215 | 289 | 524 | 628 | 588 |
| Tax | −46 | −59 | −109 | −130 | −122 |
| Net profit | 169 | 230 | 416 | 498 | 465 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 741 | 624 | 696 | 938 | 767 |
| Equity | 220 | 449 | 466 | 548 | 516 |
| Long-term debt | 0 | 0 | — | — | — |
| Short-term debt | 521 | 175 | 230 | 389 | 252 |
| Total debt | 521 | 175 | 230 | 389 | 252 |
EBITDA margin
27.6%
This company
15.8%
Market median
+75% vs market
20202024
Equity ratio
67.2%
This company
38.2%
Market median
+76% vs market
20202024
Return on equity
90.2%
This company
18.4%
Market median
+390% vs market
20202024
Net profit margin
21.9%
This company
8.1%
Market median
+170% vs market
20202024
Asset turnover
2.77×
This company
1.12×
Market median
+147% vs market
20202024
Debt / equity
0.49×
This company
0.62×
Market median
+21% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Deputy Board Member | 2022 | |
| Board of Directors | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Medspec AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Miroslaw Pawel Olczykowski | Deputy Board Member | 0 companies |
| Rafal Pawel Olczykowski | Board of Directors | 0 companies |